TICKERNOMICS Sign up
Last Update: 2024-12-27 15:30:07
Bone Biologics Corp ( BBLG ) https://www.bonebiologics.com
0.95USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-84.17%
BBLG
SPY
32.66%
-99.89%
BBLG
SPY
108.59%
-99.98%
BBLG
SPY
302.52%
BBLG
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.67
-1.90
0.21
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.40
0.00
0.44
-406.58
0.00
0.70
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.1424
41.56
-81.67
-0.32
Other Earnings and Cash Flow Stats:
Bone Biologics Corp ( BBLG ) Net Income TTM ($MM) is -4.14
Bone Biologics Corp ( BBLG ) Operating Income TTM ($MM) is -3.82
Bone Biologics Corp ( BBLG ) Owners' Earnings Annual ($MM) is 0.00
Bone Biologics Corp ( BBLG ) Current Price to Owners' Earnings ratio is 0.00
Bone Biologics Corp ( BBLG ) EBITDA TTM ($MM) is -1.76
Bone Biologics Corp ( BBLG ) EBITDA Margin is 0.00%
Capital Allocation:
Bone Biologics Corp ( BBLG ) has paid 0.00 dividends per share and bought back -1.361611 million shares in the past 12 months
Bone Biologics Corp ( BBLG ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Bone Biologics Corp ( BBLG ) Interest-bearing Debt ($MM) as of last quarter is 0
Bone Biologics Corp ( BBLG ) Annual Working Capital Investments ($MM) are -1
Bone Biologics Corp ( BBLG ) Book Value ($MM) as of last quarter is 3
Bone Biologics Corp ( BBLG ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Bone Biologics Corp ( BBLG ) has 3 million in cash on hand as of last quarter
Bone Biologics Corp ( BBLG ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Bone Biologics Corp ( BBLG ) has 1 common shares outstanding as of last quarter
Bone Biologics Corp ( BBLG ) has 0 million USD of preferred stock value
Academic Scores:
Bone Biologics Corp ( BBLG ) Altman Z-Score is -26.91 as of last quarter
Bone Biologics Corp ( BBLG ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Bone Biologics Corp ( BBLG ) largest shareholder is owning shares at 0.00 ($MM) value
Deina H Walsh(an insider) Bought 1000 shares of Bone Biologics Corp ( BBLG ) for the amount of $5120.00 on 2023-09-13
5.21% of Bone Biologics Corp ( BBLG ) is held by insiders, and 4.59% is held by institutions
Bone Biologics Corp ( BBLG ) went public on 2016-03-31
Other Bone Biologics Corp ( BBLG ) financial metrics:
FCF:-4.79
Unlevered Free Cash Flow:0.00
EPS:-2.15
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-99.25
Beta:-0.32
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Bone Biologics Corp ( BBLG ) :
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.